William Rollefson, MD
Cardiovascular Disease · Little Rock, ARNPI 1366436750
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $61,700 of the $73,614 with a category attached, or 83.8%. 20 manufacturers reported payments, led by Endologix LLC at 57.4% of the total. Reporting peaked in 2019 at $28,518 and has fallen 94.1% since, to $1,672 in 2025. Among cardiovascular disease clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 227 payments — averaging $324.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Endologix LLC$42K
- Terumo Medical Corporation$20K
- Abbott$5K
- Edwards Lifesciences$2K
- Cardiovascular Systems Inc.$1K
- Shockwave Medical, Inc$836
- plus $2K from 14 others
Across 116 payments — averaging $3780.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$338K
- Boston Scientific$77K
- Cardiovascular Systems Inc.$24K
What the payments were for
- Consulting fees$61,70084%
- Travel & lodging$3,0664%
- Food & beverage$8,56712%
- Other$2820%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Endologix LLC | 35 | $42,233 |
| Terumo Medical Corporation | 19 | $20,213 |
| Abbott | 89 | $5,135 |
| Edwards Lifesciences | 15 | $1,526 |
| Cardiovascular Systems Inc. | 17 | $1,458 |
| Shockwave Medical, Inc | 8 | $836 |
| Medtronic(2 entities) | 8 | $634 |
| Boston Scientific | 10 | $505 |
| Abiomed | 4 | $379 |
| Livanova USA, Inc. | 2 | $165 |
| Bolton Medical Inc | 1 | $147 |
| Pfizer | 9 | $147 |
| Cardiva Medical, Inc. | 1 | $51 |
| Novartis | 2 | $42 |
| Biotronik Inc. | 2 | $41 |
| Inari Medical, Inc. | 1 | $28 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Johnson & Johnson | 1 | $20 |
| Lexicon Pharmaceuticals, Inc. | 1 | $17 |
| Novo Nordisk | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AFX2 Bifurcated Endograft System$26,700
- Optitorque$20,000
- Heartrail$20,000
- TR Band$20,000
- Glidesheath$20,000
- AFX$15,414
- Peripheral Orbital Atherectomy System$1,086
- Edwards SAPIEN 3 Transcatheter Heart Valve$910
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$680
- NAVITOR$393
- MitraClip$296
- Impella$296
- PORTICO$282
- AMPLATZER AMULET$242
- Portico Transcatheter Aortic Heart Valve$160
- CoreValve Evolut$152
- ENDURANT IIS$150
- Xience Sierra Coronary Stent System$149
- Grafts$147
- COROFLOW$146
How this compares
$73,614 in reported general payments places this provider in the 95th percentile of 130 cardiovascular disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 281 | $284,641 |
| XareltoRivaroxaban | 95 | $97,457 |
| EntrestoSacubitril/Valsartan | 71 | $57,983 |
| Metoprolol Succinate | 825 | $8,705 |
| JardianceEmpagliflozin | 12 | $7,137 |
| FarxigaDapagliflozin Propanediol | 11 | $6,857 |
| ClopidogrelClopidogrel Bisulfate | 778 | $6,816 |
| Prasugrel Hcl | 68 | $5,218 |
| Potassium Chloride | 228 | $4,299 |
| Dofetilide | 15 | $3,890 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 13 | $3,431 |
| Bumetanide | 121 | $3,419 |
| Atorvastatin Calcium | 424 | $3,324 |
| Losartan Potassium | 319 | $3,203 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 256 | $2,313 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $147 | $284,641281 claims |
| Johnson & JohnsonXarelto | $20 | $97,45795 claims |
| NovartisEntresto | $42 | $57,98371 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 130 cardiovascular disease providers in Arkansas.
Other cardiovascular disease in Little Rock
- Ian CawichLittle Rock$294K
- Andre PaixaoLittle Rock$73K
- Wesley LaneLittle Rock$46K
- Omar QaqishLittle Rock$45K
- Barry UretskyLittle Rock$36K
- Freddy ChrismanLittle Rock$26K
- Forrest GloverLittle Rock$17K
- Clayton BorgLittle Rock$14K
- David MegoLittle Rock$14K
- Michael HuberLittle Rock$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.